Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam’s Next Move: Testing RSV Candidate In Naturally-Infected Adults, Pediatric Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

RNAi-focused biotech also says it anticipates IND filings this year for hypercholesterolemia and liver cancer candidates.

You may also be interested in...



Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy

Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.

Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy

Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.

Alnylam Strengthens IP Position With Acquisition Of Nucleonics Patent Estate

RNAi-focused biotech calls acquisition inexpensive, will prevent potential end-around of its intellectual property.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel